texas oncology more breakthroughs. more victories
Some of our cancer centers are experiencing issues.  View More Important Notifications x

Austin North Research and Clinical Trials

Texas Oncology-Austin North participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Austin North Suite 120 (Expand)

Brain Cancer

Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

Breast Cancer

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

Cervical Cancer

PH3 adv CC

A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11) Read Moreabout PH3 adv CC

Phase: III

Endometrial Cancer

Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma

A Phase 3 Randomized Open-label Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (MK-3475-C93/GOG-3064) Read Moreabout Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma

Phase: III

INCMGA00012 Endo Cancer

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204) Read Moreabout INCMGA00012 Endo Cancer

Phase: II

Fallopian Tube Cancer

PH3 Pac-Carbo-Oreg EO FT or PC

A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035) Read Moreabout PH3 Pac-Carbo-Oreg EO FT or PC

Phase: III

Ph2 AKT Pac vs Ova fall and Peri

An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri

Phase: II

Ph2 EpiO Peri FallTC

PICCOLO: A Phase 2 Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0419) Read Moreabout Ph2 EpiO Peri FallTC

Phase: II

Gastric Cancer

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

Head and Neck Cancer

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

Lung Cancer

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

Lymphomas

STAR BV in pts w/1L cHL or PTCL

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read Moreabout STAR BV in pts w/1L cHL or PTCL

Phase: II

Ovarian Cancer

Ph1b/2 XMT-1536 ST NaPi2b

A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048) Read Moreabout Ph1b/2 XMT-1536 ST NaPi2b

Phase: II

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

STAR Ph2 VS-6766 Fak-Inhib LGSOC

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052) Read Moreabout STAR Ph2 VS-6766 Fak-Inhib LGSOC

Phase: II

PH3 Pac-Carbo-Oreg EO FT or PC

A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035) Read Moreabout PH3 Pac-Carbo-Oreg EO FT or PC

Phase: III

Ph2 AKT Pac vs Ova fall and Peri

An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri

Phase: II

PH3 Alpe BYL719 Olap BRCA OC

EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301) Read Moreabout PH3 Alpe BYL719 Olap BRCA OC

Phase: III

Ph2 EpiO Peri FallTC

PICCOLO: A Phase 2 Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0419) Read Moreabout Ph2 EpiO Peri FallTC

Phase: II

Peritoneal Cancer

PH3 Pac-Carbo-Oreg EO FT or PC

A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035) Read Moreabout PH3 Pac-Carbo-Oreg EO FT or PC

Phase: III

Ph2 AKT Pac vs Ova fall and Peri

An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri

Phase: II

Ph2 EpiO Peri FallTC

PICCOLO: A Phase 2 Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0419) Read Moreabout Ph2 EpiO Peri FallTC

Phase: II

Solid Tumors

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

Texas Oncology-Austin North Suite 300 (Expand)

Brain Cancer

Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

Breast Cancer

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

Cervical Cancer

PH3 adv CC

A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11) Read Moreabout PH3 adv CC

Phase: III

Endometrial Cancer

Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma

A Phase 3 Randomized Open-label Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (MK-3475-C93/GOG-3064) Read Moreabout Ph 3 Pemb v Plat Dbl dMMR Endo Carcinoma

Phase: III

INCMGA00012 Endo Cancer

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204) Read Moreabout INCMGA00012 Endo Cancer

Phase: II

Fallopian Tube Cancer

PH3 Pac-Carbo-Oreg EO FT or PC

A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035) Read Moreabout PH3 Pac-Carbo-Oreg EO FT or PC

Phase: III

Ph2 AKT Pac vs Ova fall and Peri

An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri

Phase: II

Ph2 EpiO Peri FallTC

PICCOLO: A Phase 2 Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0419) Read Moreabout Ph2 EpiO Peri FallTC

Phase: II

Gastric Cancer

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

Head and Neck Cancer

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

Lung Cancer

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

Lymphomas

STAR BV in pts w/1L cHL or PTCL

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read Moreabout STAR BV in pts w/1L cHL or PTCL

Phase: II

Ovarian Cancer

Ph1b/2 XMT-1536 ST NaPi2b

A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048) Read Moreabout Ph1b/2 XMT-1536 ST NaPi2b

Phase: II

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II

STAR Ph2 VS-6766 Fak-Inhib LGSOC

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052) Read Moreabout STAR Ph2 VS-6766 Fak-Inhib LGSOC

Phase: II

PH3 Pac-Carbo-Oreg EO FT or PC

A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035) Read Moreabout PH3 Pac-Carbo-Oreg EO FT or PC

Phase: III

Ph2 AKT Pac vs Ova fall and Peri

An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri

Phase: II

PH3 Alpe BYL719 Olap BRCA OC

EPIK-O: A Phase III multi-center randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy in participants with no germline BRCA mutation detected platinum-resistant or refractory high-grade serous ovarian cancer (CBYL719K12301) Read Moreabout PH3 Alpe BYL719 Olap BRCA OC

Phase: III

Ph2 EpiO Peri FallTC

PICCOLO: A Phase 2 Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0419) Read Moreabout Ph2 EpiO Peri FallTC

Phase: II

Peritoneal Cancer

PH3 Pac-Carbo-Oreg EO FT or PC

A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035) Read Moreabout PH3 Pac-Carbo-Oreg EO FT or PC

Phase: III

Ph2 AKT Pac vs Ova fall and Peri

An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001) Read Moreabout Ph2 AKT Pac vs Ova fall and Peri

Phase: II

Ph2 EpiO Peri FallTC

PICCOLO: A Phase 2 Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (IMGN853-0419) Read Moreabout Ph2 EpiO Peri FallTC

Phase: II

Solid Tumors

Ph2 TJ004309 + Atezo OC/ST

A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103) Read Moreabout Ph2 TJ004309 + Atezo OC/ST

Phase: II